Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine through CRISPR gene editing and related core technologies. The company's mission centers on transforming the lives of people with severe diseases by developing and commercializing potentially curative… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Intellia Therapeutics, Inc. does
In the company’s own words
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine through CRISPR gene editing and related core technologies. The company's mission centers on transforming the lives of people with severe diseases by developing and commercializing potentially curative treatments that address the root causes of disease rather than merely managing symptoms.
The company's lead programs represent the first in vivo genome editing product candidates to advance into Phase 3 clinical development. Lonvoguran ziclumeran, or lonvo-z, is designed to treat hereditary angioedema by inactivating the kallikrein B1 gene in the liver, with the goal of achieving lifelong control of HAE attacks through a single intravenous infusion. Nexiguran ziclumeran, or nex-z, targets transthyretin amyloidosis by inactivating the TTR gene, offering the potential to halt and reverse disease progression in both hereditary and wild-type forms of the condition. Both candidates employ Intellia's proprietary in vivo lipid nanoparticle delivery technology and are administered as one-time outpatient treatments.
Beyond its lead programs, Intellia is expanding its pipeline through independent development and strategic collaborations. The company leverages a decade-plus of research and development experience in multi-modal CRISPR gene editing, oligonucleotide technologies, and lipid nanoparticle delivery systems. Intellia maintains a significant intellectual property portfolio encompassing foundational CRISPR/Cas9 patents and improvements to these systems, with wholly owned and in-licensed patents expected to provide protection through at least 2037.
The company's strategy encompasses advancing clinical development of lead candidates, building fully integrated commercial-stage infrastructure in preparation for potential product launches, expanding its pipeline using proprietary technologies, and collaborating with partners to extend technology reach and maximize return on investment. Intellia has established strategic relationships including a co-development and co-promotion agreement with Regeneron Pharmaceuticals for the ATTR program, as well as collaborations with AvenCell Therapeutics and Kyverna Therapeutics for cell therapy development. The company website is www.intelliatherapeutics.com.
Company details
- Sector
- Materials
- Industry
- Chemicals
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1652130
- SIC
- 2835
Financial performance, year by year
Fiscal 2016–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Intellia Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Intellia Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Intellia Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Intellia Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Intellia Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”